Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Rani Therapeutics Holdings, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-05-22Dec-31-21Dec-05-21Dec-31-20Dec-31-19
   10-K8-K10-K8-K10-KS-1
Revenues  0.036.62.72.70.51.0
            Revenue growth  -100.0%1247.3%488.1% -52.8% 
Cost of goods sold  0.063.50.054.30.028.0
Gross profit  0.0-26.82.7-51.60.5-27.1
            Gross margin   -73.3%100.0%-1899.1%100.0%-2764.6%
Selling, general and administrative   [+]26.826.827.827.85.03.5
Research and development  36.6 26.5 12.0 
Other operating expenses   9.8 -27.8 -3.5
EBITDA   [+]-62.9 -51.1 -16.0-26.5
            EBITDA margin   -173.3%-1880.8%-1899.1%-3453.5%-2706.9%
Depreciation and amortization  0.5 0.5 0.60.6
EBIT   [+]-63.5-63.5-51.6-51.6-16.5-27.1
            EBIT margin   -173.3%-1899.1%-1899.1%-3581.0%-2764.6%
Interest expense, net   [+]1.1 0.5 0.1-0.4
Other income (expense), net   [+]1.20.2-1.0-1.4-0.10.1
Pre-tax income  -63.3-63.3-53.0-53.0-16.7-26.6
Income taxes  0.10.10.00.00.00.0
            Tax rate       0.0%
Minority interest  -32.8-32.8-44.8-44.8-16.7 
Net income  -30.6-63.3-8.3-53.10.00.0
            Net margin   -173.0%-306.6%-1953.9%0.0%0.0%
   
Basic EPS   [+]($1.28) ($426.49)   
Diluted EPS   [+]($1.28) ($0.43)   
   
Shares outstanding (basic)   [+]23.8 0.0   
Shares outstanding (diluted)   [+]23.8 19.5   
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy